Samsung Biologics Co Ltd (207940) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.051x

Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has a cash flow conversion efficiency ratio of 0.051x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩619.30 Billion ≈ $419.69 Million USD) by net assets (₩12.18 Trillion ≈ $8.25 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Samsung Biologics Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Samsung Biologics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 207940 total debt and obligations for a breakdown of total debt and financial obligations.

Samsung Biologics Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Samsung Biologics Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Hindustan Aeronautics Limited NSE:HAL	0.216x
Foshan Haitian Flavouring and Food Co Ltd SHG:603288	0.037x
Baidu Inc F:B1C	0.009x
Advanced Info Service Public Company Limited BK:ADVANC	0.311x
DAIKIN INDUSTR.UNSP.ADR F:DKIA	N/A
Fresnillo plc F:FNL	0.025x
Kering SA PA:KER	0.084x
ANGLO AMERICAN SP.ADR 1/2 F:NGLD	N/A

Annual Cash Flow Conversion Efficiency for Samsung Biologics Co Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Samsung Biologics Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Samsung Biologics Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩10.90 Trillion ≈ $7.39 Billion	₩1.66 Trillion ≈ $1.12 Billion	0.152x	-10.23%
2023-12-31	₩9.83 Trillion ≈ $6.66 Billion	₩1.67 Trillion ≈ $1.13 Billion	0.169x	+59.79%
2022-12-31	₩8.98 Trillion ≈ $6.09 Billion	₩953.05 Billion ≈ $645.87 Million	0.106x	+16.46%
2021-12-31	₩4.99 Trillion ≈ $3.38 Billion	₩454.60 Billion ≈ $308.07 Million	0.091x	+107.27%
2020-12-31	₩4.60 Trillion ≈ $3.12 Billion	₩202.09 Billion ≈ $136.95 Million	0.044x	+1784.58%
2019-12-31	₩4.35 Trillion ≈ $2.95 Billion	₩10.15 Billion ≈ $6.88 Million	0.002x	+129.35%
2018-12-31	₩4.16 Trillion ≈ $2.82 Billion	₩-33.02 Billion ≈ $-22.38 Million	-0.008x	-121.09%
2017-12-31	₩3.98 Trillion ≈ $2.69 Billion	₩149.82 Billion ≈ $101.53 Million	0.038x	+345.46%
2016-12-31	₩4.08 Trillion ≈ $2.77 Billion	₩-62.66 Billion ≈ $-42.46 Million	-0.015x	+83.96%
2015-12-31	₩2.77 Trillion ≈ $1.88 Billion	₩-265.51 Billion ≈ $-179.93 Million	-0.096x	+44.27%
2014-12-31	₩630.73 Billion ≈ $427.44 Million	₩-108.30 Billion ≈ $-73.39 Million	-0.172x	--

About Samsung Biologics Co Ltd

KO:207940 Korea Biotechnology

Market Cap

$31.37 Billion

₩46.29 Trillion KRW

Market Cap Rank

#842 Global

#16 in Korea

Share Price

₩1000000.00

Change (1 day)

+0.00%

52-Week Range

₩991000.00 - ₩1000000.00

All Time High

₩1000000.00